Literature DB >> 1910957

The effects of etidronate on trabecular bone remodeling in postmenopausal spinal osteoporosis: a randomized study comparing intermittent treatment and an ADFR regime.

T Steiniche1, C Hasling, P Charles, E F Eriksen, F Melsen, L Mosekilde.   

Abstract

Thirty-seven patients were randomized to receive intermittent cyclic etidronate (400 mg/day oral for 2 weeks, followed by 13 weeks off treatment) or an ADFR treatment (100 micrograms/day oral triiodothyronine for 7 days, followed by 400 mg/day etidronate for 2 weeks and 12 weeks off treatment). Supplemental calcium (120 mg/day) and vitamin D3 (400 IU/day) were given throughout the study period to all patients. Biochemical analyses, iliac-crest bone biopsies, and lumbar bone mineral content (BMC) measurements were performed before and during 60 weeks of treatment. Sixteen patients in the intermittent cyclic etidronate group and 15 in the ADFR group completed 60 weeks of treatment. Serum alkaline phosphatase decreased from 185 (43) (mean, (SD] to 144 (35) (p less than 0.001) and from 221 (69) to 156 (43) (p less than 0.002) during intermittent cyclic etidronate treatment and ADFR treatment, respectively, without any significant changes in renal hydroxyproline excretion. Final resorption depth, trabecular bone activation frequency, and bone formation rate decreased significantly from 51.5 (48.4/60.0) microns (median (25%/75% quartiles] to 44.0 (39.6/46.2) microns (p less than 0.04), from 0.30 (0.17/0.62) year-1 to 0.10 (0.02/0.19) year-1 (p less than 0.03) and from 0.035 (0.020/0.081) microns3/microns2/day to 0.015 (0.002/0.025) microns3/microns2/day, p less than 0.03 respectively, during intermittent cyclic etidronate treatment, but were unchanged during ADFR treatment. No significant changes in trabecular bone volume, bone balance per remodeling cycle, or BMC were noted in either treatment group; no evidence of osteomalacia was found. Intermittent cyclic etidronate treatment may be effective in preventing bone loss and in decreasing the risk of trabecular plate perforation, and thereby maintaining the integrity of bone architecture, in postmenopausal osteoporosis.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1910957     DOI: 10.1016/8756-3282(91)90038-k

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  12 in total

Review 1.  Mechanisms of bone loss and gain in untreated and treated osteoporosis.

Authors:  Juliet Compston
Journal:  Endocrine       Date:  2002-02       Impact factor: 3.633

2.  Calcitonin versus etidronate for the treatment of postmenopausal osteoporosis: a meta-analysis of published clinical trials.

Authors:  J M Cardona; E Pastor
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

Review 3.  Bisphosphonates and osteoporosis.

Authors:  O H Sørensen; T Storm; G Thamsborg; H A Sørensen; G Kollerup; T Steiniche; F Melsen; H K Genant
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

4.  Bone histomorphometry.

Authors:  F Melsen; T Steiniche
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

5.  Actions of osteoporosis treatments on bone histomorphometric remodeling: a two-fold principal component analysis.

Authors:  X Wan; Y Zhao; R Burge; Y Jiang
Journal:  Osteoporos Int       Date:  2013-07-24       Impact factor: 4.507

Review 6.  Rationale for the use of alendronate in osteoporosis.

Authors:  J A Kanis; B J Gertz; F Singer; S Ortolani
Journal:  Osteoporos Int       Date:  1995-01       Impact factor: 4.507

Review 7.  New bisphosphonates in osteoporosis.

Authors:  H Fleisch
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

Review 8.  Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  C J Dunn; A Fitton; E M Sorkin
Journal:  Drugs Aging       Date:  1994-12       Impact factor: 3.923

9.  A comparison of the effects of oestrogen/progestogen, high-dose oral calcium, intermittent cyclic etidronate and an ADFR regime on calcium kinetics and bone mass in postmenopausal women with spinal osteoporosis.

Authors:  C Hasling; P Charles; F T Jensen; L Mosekilde
Journal:  Osteoporos Int       Date:  1994-07       Impact factor: 4.507

Review 10.  Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.

Authors:  G A Wells; A Cranney; J Peterson; M Boucher; B Shea; V Robinson; D Coyle; P Tugwell
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.